## WAT: Waters Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -2.0% below STRENGTH zone (4.0-10.0%); PEG 6.41 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($356.32)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Waters (WAT) Sees Price Target Raised by Wells Fargo | WAT Stock News**
- Source: GuruFocus | 20251215T192822 | Somewhat-Bullish | Relevance: 100%
- Wells Fargo has maintained its "Equal-Weight" rating on Waters Corporation (WAT) but raised its price target for the company from $385 to $415. This adjustment reflects a 7.79% increase based on analyst Brandon Couillard's review. The article also provides historical analyst ratings and a company overview, including its revenue breakdown and future plans for a merger with BD's life science and diagnostics business in early 2026.

**2. Agilent Technologies (NYSE:A) - Stock Analysis**
- Source: Simply Wall Street | 20251215T190736 | Neutral | Relevance: 65%
- This report provides a comprehensive stock analysis of Agilent Technologies (NYSE:A), highlighting its strong position in life sciences, diagnostics, and applied chemical markets. The company shows sustained growth driven by healthcare demand and innovative technologies, with analysts forecasting a stock price increase of 21.7%. Financials indicate a healthy balance sheet and consistent dividend payouts.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Wells Fargo | $415 | $385 | +8% |
| 2025-12-10 | Wolfe Research | $480 | $0 | 0% |
| 2025-12-02 | Morgan Stanley | $423 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Wells Fargo | main | Equal-Weight |
| 2025-12-10 | Wolfe Research | up | Outperform |
| 2025-12-02 | Morgan Stanley | init | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 12.9% (+3.3%)
- Blackrock Inc.: 10.2% (-7.6%)
- Fundsmith LLP: 6.6% (+9.6%)
- Massachusetts Financ: 4.5% (+44.3%)
- State Street Corpora: 4.5% (+0.1%)

### Key Risks

1. Valuation stretched: PEG 6.4x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 6.41 signals overvaluation risk, limited margin of safety. Forward P/E 26.4x stretched relative to 9% growth. Quality metrics strong (ROE 33%, ROA 12%, margin 21%). Analyst sentiment positive (1 raises, avg +8%). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $22.5B |
| Beta | 1.16 |
| 52W Range | $275.05 - $423.56 |
| Short Interest | 5.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 6.41 |
| Forward P/E | 26.4 |
| Current P/E | 28.7 |
| YoY Growth | 9.0% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at -2.0% (minimal 5-day change). Below STRENGTH zone by 6.0pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.1%) - potential reversal signal. AM_20 at -4.0% indicates price below own 20MA trend. Underperforming sector by 3.7pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.11x) but short-term weakness (below SMA20). MACD histogram bearish (-4.13), momentum weakening. RSI neutral at 44. OFD pattern: -SUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.04% (CS: 17) | Weak |
| RSI_14 | 44.4 | Neutral |
| MACD Histogram | -4.13 | Bearish |
| vs SMA20 | 0.960x | Below |
| vs SMA50 | 1.019x | Above |
| vs SMA200 | 1.111x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $376.94
- **Stop Loss:** $356.32 (5.5% risk)
- **Target:** $397.56 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 52
- **Position Value:** $19,600.88
- **Portfolio %:** 19.60%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-02-11 (Est: $4.51)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.22 | $3.40 | +5.5% |
| 2025Q2 | $2.94 | $2.95 | +0.3% |
| 2025Q1 | $2.22 | $2.25 | +1.2% |
| 2024Q4 | $4.03 | $4.10 | +1.7% |

---
*RULE-based L3 | 2026-01-07 01:41 | MRS_20*